Lantheus为扩大癌症诊断工具购买了10亿多美元的长青热学药物。 Lantheus buys Evergreen Theragnostics for over $1 billion to expand its cancer diagnostic tools.

Lantheus Holdings 以超过 10 亿美元的全现金交易收购 Evergreen Theragnostics，其中包括 2.5 亿美元的预付款和高达 7.525 亿美元的潜在里程碑付款。 Lantheus Holdings is acquiring Evergreen Theragnostics for over $1 billion in an all-cash deal, including an upfront payment of $250 million and potential milestone payments up to $752.5 million. 这一收购加强了Lantheus的癌症放射药剂组合,增加了用于神经内分泌肿瘤的PET诊断剂OCTEVY,并增强了其制造和发展能力。 This acquisition bolsters Lantheus' cancer radiopharmaceutical portfolio, adding OCTEVY, a PET diagnostic agent for neuroendocrine tumors, and enhancing its manufacturing and development capabilities. 预计这一交易将于今年晚些时候结束,将扩大Lantheus的肿瘤诊断管道,并加强其在市场中的地位。 The deal is expected to close later this year, expanding Lantheus' oncology diagnostic pipeline and strengthening its position in the market.